Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Kyverna Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -70.82%, provide a clear picture of how effectively KYTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, KYTX competes directly with industry leaders such as IVVD and ANRO. With a market capitalization of $453.04M, it holds a significant position in the sector. When comparing efficiency, KYTX's gross margin of N/A stands against IVVD's 91.71% and ANRO's N/A. Such benchmarking helps identify whether Kyverna Therapeutics Inc is trading at a premium or discount relative to its financial performance.
